# Patent

## Title
Composition for inhibiting immune cell proliferation comprising sialyllactose or derivative thereof and method thereof


## Abstract

Provided are a composition for inhibiting immune cell proliferation, including
sialyllactose or a derivative thereof as an active ingredient, and a method of
inhibiting immune cell proliferation, wherein the composition and the method
may decrease expression of chemokines, decrease expression of pro-inflammatory
cytokines, decrease production of inflammatory mediators, decrease expression
of COX2, and decrease production of PEG2, and therefore, may be useful for the
prevention or treatment of atopic dermatitis or arthritis.



## Background
### TECHNICAL FIELD

The present disclosure relates to a composition for inhibiting immune cell
proliferation including sialyllactose or a derivative thereof as an active
ingredient, and a method of inhibiting immune cell proliferation.

### BACKGROUND ART

Osteoarthritis (OA) is a degenerative joint disease primarily caused by
inhibition of cartilage extracellular matrix (ECM) synthesis and promotion of
cartilage is tissue destruction. Many etiological risk factors and
pathophysiological processes associated with aging contribute to the
progression of osteoarthritis. Joint instability, mechanical stress including
injury, and aging-related factors that predispose one to osteoarthritis are
potential osteoarthritis-causing mechanisms. These factors activate
biochemical pathways in chondrocytes which are a unique cell type that
synthesizes various catabolic and anabolic factors, leading to degradation of
the ECM by matrix metalloproteinase (Mmp) and cessation of ECM synthesis via
dedifferentiation and apoptosis of chondrocytes (Pelletier J P et al.,
Arthritis Rheum., 44:1237-47, 2001). In particular, cartilage tissue that
constitutes a joint is not normally regenerated in vivo once it is damaged. If
cartilage tissue in a joint is damaged, the cartilage tissue damage impedes
daily activities with severe pain. If the damage becomes chronic, it causes
fatal osteoarthritis which interferes with normal life or professional
activities.

Until now, therapeutic agents for arthritis have not been developed.
Generally, non-steroidal anti-inflammatory drugs (NSAIDs) are used for the
purpose of alleviating joint inflammation. However, since NSAID-based drugs
are primarily intended to temporarily relieve joint inflammation, NSAID-based
drugs do not provide adequate treatment for osteoarthritis which is a non-
inflammatory arthritis that requires enhancement of cartilage formation and
inhibition of cartilage destruction (Pritchard M H et al., Annals of the
Rheumatic Diseases, 37:493-503, 1978). Such NSAIDs are suitable as a
therapeutic agent for the prevention of inflammation in rheumatoid arthritis
which is an inflammatory arthritis. However, it is pointed out that NSAIDs
accelerate cartilage damage or have adverse effects on the cardiovascular
system, gastrointestinal tract, kidney, liver, etc.

Further, an autologous osteochondral transplantation method which was
developed for cartilage formation involves collecting cartilage and
